Calcium channel blockers in cerebral ischaemia

Bibliography

• SEISJO BK: Mechanisms of ischaemic brain damage. Grit. Care Med. (1988) 16:895–963.
   Web of Science ®Google Scholar
• MILLER AJ: Multiple calcium channels and neuronal function. Science (1987) 235:46–52.
   PubMed Web of Science ®Google Scholar
• SEISJO BK: Historical overview: calcium, ischaemia and death of brain cells. Ann. NYAcad. Sci. (1988) 522:638–661.
   PubMed Web of Science ®Google Scholar
• SIESJO BK: Pathophysiology and treatment of focal cerebral ischaemia. Part L Pathophysiology. j Neuro-surg. (1992) 77:169–184.
   PubMed Web of Science ®Google Scholar
• SIESJO BK: Pathophysiology and treatment of focal cerebral ischaemia. Part II. Mechanisms of damage and treatment. Neurosurg (1992) 77:337–354.
   Google Scholar
• CHOI DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623–634.
   PubMed Web of Science ®Google Scholar
• UEMATSU D, GREENBERG JH, REIVICH M, HICKEY WF: Direct evidence for calcium-induced ischaemic and reperfusion injury. Ann. Neurol (1989) 26:280–283.
   PubMed Web of Science ®Google Scholar
• YUE T-L, LYSKO PG, FEUERSTEIN G: Production of plate-let-activating factor from rat cerebellar granule cells in culture. J. Neurochem. (1990) 57:1809–1811.
   Google Scholar
• KORNECKI E, EHRLICH H: Neuroregulatory and neuropathological actions of thephosph olipid platelet-activating factor. Science (1988) 240:1792–1794.
   PubMed Web of Science ®Google Scholar
• ROTHMAN SM, OLNEY JW: Glutamate and the patho-physiology of hypoxic-ischaemic brain damage. Ann. Neurol (1986) 19:105–111.
   PubMed Web of Science ®Google Scholar
• GINSBERG MD: Efficacy of calcium channel blockers in brain ischaemia: a critical assessment. In: Pharmacology of Cerebral Ischaemia. Kriegelstein J (Ed.), CRC press, Boca Raton, FL (1989).
   Google Scholar
• NAKAYAMA H, GINSBERG MD, DIETRICH WD: (s)-Emopamil, a novel calcium channel blacker and sero-tonin S2 antagonist markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology (1988) 38: 1667-1673.
   Google Scholar
• FLECKENSTEIN A: Experimental facts and therapeutic prospects. In: Calcium Antagonism in Heart and Smooth Muscle. John Wiley & Sons, New York (1983).
   Google Scholar
• GODFRAIND T, MILLER R, WIBO M: Calcium antagonists and calcium entry blockade. Pharmacol. Rev. (1986) 38:321–416.
   PubMed Web of Science ®Google Scholar
• TRIGGLE DJ: Effect of calcium on excitable membranes and neurotransmitter actions. Prog. Surg. Mem. Sci. (1972) 5:267–331.
   Google Scholar
• MARTIN-MOUTOT N, CHARVIN N, LEVEQUE C et al: Inter-action of SNARE complexes with P/Q Type calcium channels in rat cerebellar synaptosomes. J. Biol Chem. (1996) 271:6567–70.
   PubMed Web of Science ®Google Scholar
• HUANG CC, HSU KS, GEAN PW: Isoproterenol potenti-ates synaptic transmission primarily by enhancing p resynap tic calcium influx via P-and/or Q Type calcium channels in the rat amygdala.j Neurosci. (1996) 16:1026–33.
   PubMed Web of Science ®Google Scholar
• NAKANISHI S, FUJII A, KIMURA T, SAKAKIBARA A, MIK-OSHIBA K: Spatial distribution of omega-agatoxin WA binding sites in mouse brain slices. J. Neurosci. Res. (1995) 41:532–539.
   PubMed Web of Science ®Google Scholar
• ELLIOTT EM, MALOUF AT, CATTERALL WA: Role of cal-cium channel subtypes in calcium transients in hippo-camp al CA3 neurones. J. Neurosci. (1995) 15:6433–44.
   PubMed Web of Science ®Google Scholar
• PASSAFARO M, ROSA P, SALA C, CLEMENTI F, SHER E: NType Ca2+ channels are present in secretory granules and are transiently translocated to the plasma mem-brane during regulated exocytosis. J. Biol. Chem. (1996) 271:30096–30104.
   PubMed Web of Science ®Google Scholar
• PICHLER M, WANG Z, GRANER-WEISS C et al: Block ofP/QType calcium channels by therapeutic concentrations of aminoglycos ide antibiotics. Biochemistry (1996) 35:14659–14664.
   PubMed Web of Science ®Google Scholar
• JACKSON HC, SCHEIDELER MA: Behavioural and anticon-vulsant effects of Ca2+ channel toxins in DBA/2 mice. Psychopharmacology (Berlin) (1996) 126:85–90.
   PubMed Web of Science ®Google Scholar
• MCBURNEY RN, DALY D. FISCHER JB et al.: New CNS-spe-cific calcium antagonists. j Neurotrauma (1992) Suppl. 2:S531–43.
   Google Scholar
• TOTTENE A, MORETTI A, PIETROBON D: Functional di-versity of P Type and R Type calcium channels in rat cerebellar neurones. J. Neurosci. (1996) 16:6353–6363.
   PubMed Web of Science ®Google Scholar
• GADBUT AP, CASH SA, NOBLE JA, RADICE TR, WEYHEN-MEYER JA: The effect of Ca2+ channel antagonists (cad-mium, omega-conotoxin GIVA, and nitrendipine on release of angiotensin II from fetal rat brain in vitro. Neurosci. Lett. (1991) 123:91–4.
   PubMed Web of Science ®Google Scholar
• PRINGLE AK, BENHAM CD, SIM L et al: Selective N Typecalcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Stroke (1996) 27:2124–2130.
   PubMed Web of Science ®Google Scholar
• REILY MD, THANABAL V, ADAMS ME: The solution struc-ture of omega-Aga-IVB, a P Type calcium channel an-tagonist from venom of the funnel web spider, Agelenopsis aperta. j Biomol. NMR (1995) 5:122–132.
   PubMed Web of Science ®Google Scholar
• Trends in Pharmacological Sciences: 1997 Receptor & IonChannel Nomenclature Supplement (Eighth Edition). In association with IUPHAR. Alexander SPH, Peters JA (Eds.), Elsevier Science Ltd., Cambridge (1997).
   Google Scholar
• VERADI G, MIKALA G, SCHWARTZ A: Molecular determi-nants of Ca2+ channel function and drug action. Trends Pharmacol. Sci. (1995) 16:43–49.
   PubMed Web of Science ®Google Scholar
• TRIGGLE DJ, LANGS DA, JANIS RA: Ca2+ channel ligands: structure-function relationships of the 1,4-dihy-dropyridines. Med. Res. Rev. (1989) 9:123–180.
   PubMed Web of Science ®Google Scholar
• TRIGGLE DJ: Calcium antagonists: history and perspec-tives. Stroke (1990) 21 (Suppl.):IV49–58.
   Google Scholar
• KOCH WJ, HUI A, SHULL GE, ELLINOR P, SCHWARTZ A:Characterization of cDNA clones encoding two putative isoform ofthe alpha-1 subunit of the dihydropyridine-sensitive voltage-dependent calcium channel isolated from rat brain and rat aorta. FEBS Lett. (1989) 250:386–388.
   PubMed Web of Science ®Google Scholar
• JAY SD, ELLIS SB, MCCUE AF et al.: Primary structure ofthe subunit of the DHP-sensitive calcium channel from skeletal muscle. Science (1990) 248:490–491.
   PubMed Web of Science ®Google Scholar
• SCOTT RH, DOLPHIN AC, BINDOKAS VP, ADAMS ME: Inhibition of neuronal Ca2+ channel currents by the funnelweb spider toxin to-Aga-IA. Mol Pharmacol. (1990) 38:711–718.
   PubMed Web of Science ®Google Scholar
• SAUTER A, RUDIN M: Calcium antagonists reduce theextent of infarction in rat middle cerebral artery occlu-sion model as determined by quantitative magnetic resonance imaging. Stroke (1986) 17:1228–1234.
   PubMed Web of Science ®Google Scholar
• BIELENBERG GW, SAUER D, NUGLISCH J et al: Effects ofemopamil on post-ischemic blood flow and neuronal damage in rat brain. Naunyn-Schmiedeberg's Arch. Phar-macol (1989) 339:230–235.
   PubMed Web of Science ®Google Scholar
• RODA JM, CARCELLER F, DIEZ TEJEDOR E, AVENDANO C:Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischaemia. Stroke (1995) 26:1888–
   PubMed Web of Science ®Google Scholar
• HADLEY MN, SZABRAMSKI JM, SPETZLER RF et al.: Theefficacy of intravenous nimodipine in the treatment of focal cerebral ischaemia in a primate model. Neurosur-gery (1989) 25:63–70.
   PubMed Web of Science ®Google Scholar
• JACEWICZ M, BRINT S, TANABE J, PUISINELLI WA: Con-tinuous nimodipine treatment attenuates cortical in-farction in rats subjected to 24 hours of focal cerebral ischaemia. .J. Cereb. Blood Flow Metab. (1990) 10:89–96.
   PubMed Web of Science ®Google Scholar
• GOTOH 0, MOHAMED AH, MCCULLOCH J eta].: Nimodip-ine and the hemodynamic and histopathological con-sequences of middle cerebral artery occlusion in the rat.j Cereb. Blood Flow Metab. (1986) 6:321–331.
   Google Scholar
• MEYER FB, ANDERSON RE, YAKESH TL, SUNDT TM: Effect of nimodipine on intracellular pH, cortical blood flow and EEG in experimental focal cerebral ischaemia. Neurosurg (1986) 64:617–626.
   Web of Science ®Google Scholar
• STEEN PA, GISROLD SE, MILDE JH et al: Nimodipine improves outcome when given after complete cerebral ischaemia in primates. Anaesthesiology (1985) 62:406–411.
   PubMed Web of Science ®Google Scholar
• GERMANO IM, BARTKOWSKI HM, CASSEL ME, PITTS ZH:The therapeutic value of nimodipine in experimental cerebral ischaemia: neurological outcome and his-topathologic findings. J. Neurosurg (1987) 67:81–87.
   PubMed Web of Science ®Google Scholar
• VIBULSRESTH S, DEITRICH WD, BUSTO R, GINSBURG MD:Failure of nimodipine to prevent ischaemic neuronal damage in rats. Stroke (1987) 18:210–216.
   PubMed Web of Science ®Google Scholar
• CALLE PA, BOGAERT MG, DE RIDDER L, BUYLAERT WA:Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat Naunyn-Schmiedeberg's Arch. Pharmacol. (1990) 341:586–591.
   Web of Science ®Google Scholar
• VVELSCH M, NUGLISCH J, KRIEGLSTEINJ: Neuroprotectiveeffect of nimodipine is not mediated by increased cerebral blood flow after transient forebrain ischaemia in rats. Stroke (1990) 21 (Sup pl.) :IV105–107.
   Google Scholar
• BIELENBERG GW, BURNIOLM, ROSEN R, KLAUS W: Effectsof nimodipine on infarct size and cerebral acidosis after middle cerebral artery occlusion in the rat. Stroke (1990) 21(Suppl.):IV90–92.
   Google Scholar
• ROD MR, AUER RN: Combination therapy wit h nimodip-ine an dizocilpine in a rat model of transient forebrain ischaemia. Stroke (1992) 23:725–732.
   PubMed Web of Science ®Google Scholar
• CERVANTES M, CHAVEZ-CARRILLO I, ANTONIO-OCAMPOA: Effects of nimodipine on multiunit activity of several brain structures following acute global cerebral ischae-mia-anoxia in cats. Bol. Estud. Med. Biol. (1992) 40:21–30.
   PubMedGoogle Scholar
• STEEN PA, NEWBERG LA, MILDE JH, MICHFNFELDER JD: Nimodipine improves cerebral blood flow and neuro-logical recovery after complete cerebral ischaemia in the dog. J. Cereb. Blood Flow Metab. (1983) 3:38–43.
   PubMed Web of Science ®Google Scholar
• STEEN PA, NEWBERG LA, MILDE JH, MICHFNFELDER JD: Cerebral blood flow and neurologic outcome when nimodipine is given after complete cerebral ischaemia in the dog. J. Cereb. Blood Flow Metab. (1984) 4:82–87.
   PubMed Web of Science ®Google Scholar
• PASCHEN W, HALLMAYER J, ROHN G: Relationship be-tween putrescine content and density of ischaemic cell damage in the brain of Mongolian gerbils: effect of nimodipine and barbiturate. Acta Neuropathol (1988) 76:388–394.
   PubMed Web of Science ®Google Scholar
• ALPS BJ, CALDER C, HASS WK, WILSON AD: Comparativeprotective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil. Br. J. Phar-macol. (1988) 93:877–883.
   PubMed Web of Science ®Google Scholar
• LEMONS V, CHEHRAZI BB, KAUTEN R, HEIN L, WAGNERFC: The effect of nimodipine on high-energy phos-phates and intracellular pH during cerebral ischaemia. Neurotrauma (1993) 10:73–81.
   PubMed Web of Science ®Google Scholar
• EASLEY CS, WARTMAN FS, KOPELMAN AE, LOUIS TM: Effects of nimodipine on brain blood flow following acute brain ischaemia in the newborn piglet Dev. Phar-macol. Ther. (1992) 18:65–70.
   Web of Science ®Google Scholar
• ARAKI T, KATO H, KOGURE K: Selective neuronal vul-nerability following transient cerebral ischaemia in the gerbil: distribution and time course. Acta Neurol. Scand (1989) 80:548–553.
   PubMed Web of Science ®Google Scholar
• BUNNELL OS, LOUIS TM, SALDANHA RL, KOPELMAN AE:Protective action of the calcium antagonists flunarizine and nimodipine on cerebral ischaemia. Med. Sci. Res. (1987) 15:1513–1514.
   Google Scholar
• FRYISAWA A, MATSUMOTO M, MATSUYAMA T eta].: Theeffect of calcium antagonist nimodipine on the gerbil model of experimental cerebral ischaemia. Stroke (1986) 17:748–752.
   Google Scholar
• MOSSAKOWSKI MJ, GODAMSKI R: Influence of the cal-cium channel blacker on the ischaemic changes in sector CA1 pyramidal neurones of Ammon's horn in Mongolian gerbils. Neuropathology (1987) 25:439–450.
   Google Scholar
• BOSHI H, SADOSHIMA S, YAO H eta].: Inhibition of ischaemia-induced dopamine release by omega-cono-toxin, a calcium channel blacker, in the striatum of spontaneously hypertensive rats: in vivo brain dialysis study. J. Neurochem. (1992) 58:298–303.
   Google Scholar
• YAMADA K TERAOKA T, MORITA S, HASEGAWA T, NA-BESHIMA T: Omega-conotoxin GVIA protects against ischaemia-induced neuronal death in the Mongolian gerbil, but not against quinolinic acid-induced neuro-toxicity in the rat. Neuropharmacology (1994) 33:251–254.
   PubMed Web of Science ®Google Scholar
• MEYER FB, ANDERSON RE, SUNDT TM: The novel dihy-dronaphthyridine Ca2+ channel blacker CI-951 im- proves CBF, brain pH; and EEG recovery in focal cere-bral ischaemia. j Cereb. Blood Flow Metab. (1990) 10:97–103.
   PubMed Web of Science ®Google Scholar
• POIGNET H, BEAUGHARD M, LECOIN G, MASSINGHAM R: Functional, behavioural, and histological changes in-duced by transient global cerebral ischaemia in rats: effects of cinnarizine and flunarizine. j Cereb. Blood Flow Metab. (1989) 9:646–654.
   PubMed Web of Science ®Google Scholar
• WANG YL, HE RR: Protective effect of dipfluzine on experimental brain oedema in rats. Chung KuoYao Li Hsueh Pao (1994) 15:201–205.
   PubMed Web of Science ®Google Scholar
• BIELENBERG GW, HAUBRUCK H, KRIEGELSTEIN J: Effects of calcium entity blacker emopamil on post-ischaemic energy metabolism of the isolated perfused rat brai n. Cereb. Blood Flow Metab. (1987) 7:489–496.
   PubMed Web of Science ®Google Scholar
• HOFFMAN HP, RASCHAK M, UNGER L: (s)-Emopamil, a novel calcium and serotonin antagonist for the treat-ment of cerebrovascular disorders ;1st communication: pharmacological profile. Arzneimittelforschung (1989) 39:304–308.
   PubMed Web of Science ®Google Scholar
• UN B, DIETRICH D, BUSTO R, GINSBURG MD: (s)-Emopamil protects against global ischaemic brain in-jury in rats. Stroke (1990) 21:1734–1739.
   PubMed Web of Science ®Google Scholar
• MORIKAWA E, GINSBURG MD, DIETRICH D, DUNCAN RC,BUSTO R: Post-ischaemic (s)-e mopamil therapy amelio-rates focal ischaemic brain injury in rats. Stroke (1991) 22:355–360.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO M, SCHELLER MS, ZORNOW MH, STRNAT MA: Effect of S-emopamil, nimodipine, and mild hy-pothermia on hippocampal glutamate concentrations after repeated cerebral ischaemia in rabbits. Stroke (1993) 24:1228–34.
   PubMed Web of Science ®Google Scholar
• FLEISCHER JE, NAKAKIMURA K, DRUMMOND JC et al.:Effect of levemopamil onneurologic and histologic outcome after cardiac arrest in cats. Grit Care Med. (1992) 20:126–134.
   PubMed Web of Science ®Google Scholar
• SEEGA J, ELGER B: Diffusion- and T2-weighted imaging: evaluation of oedema reduction in focal cerebral ischae - m i a by the calcium and serotonin antagonist levemopamil. Maga Reson. Imaging (1993) 11:401–9.
   PubMed Web of Science ®Google Scholar
• HEIM C, SIEKLUCKA M, SONTAG KH: Levemopamil injec-tion after cerebral oligemia reduces spatial memory deficits in rats. Pharmacol Biochem. Behav. (1994) 48:613–619.
   PubMed Web of Science ®Google Scholar
• ELGER B, SEEGA J, BRENDEL R: Magnetic resonanceimaging study on the effect of levemopamil on the size of intracerebral haemorrhage in rats. Stroke (1994) 25:1836–1841.
   PubMed Web of Science ®Google Scholar
• GOMI S, GREENBERG JH, CROUL S, REIVICH M: Failure oflevemopamil to improve histological outcome follow-ing temporary occlusion of the middle cerebral artery in cats. J. Neurol. Sci. (1995) 130:128–133.
   PubMed Web of Science ®Google Scholar
• CHEN T, KATO H, BAN H et al.: Protective effects of anovel calcium antagonist with plate let-activating factor-antagonistic action, F-0401, against ischaemic brain damage. Arch. Int. Pharmacol Ther. (1994) 327:266–278.
   PubMedGoogle Scholar
• CHRISTIE-POPE BC, PALMER GC: Modulation of ischae-mic-induced damage to cerebral adenylate cyclase in gerbils by calcium channel blockers. Metab. Brain Dis. (1986) 1:249–261.
   PubMed Web of Science ®Google Scholar
• ABIKO H, MIZOI K, SUZUKI J, OBA M, YOSHIMOTO T:Cerebral protective effect of flunarizine in a canine model of cerebral ischaemia. Neurol. Res. (1988) 10:145–150.
   PubMedGoogle Scholar
• KUCHARCZYK J, CHEW W, DERU GIN N eta].: Nicardipinereduces ischaemic brain injury: magnetic resonance imaging/spectroscopy study in cats. Stroke (1989) 20:268–274.
   Google Scholar
• YOSHIDOMI M, HAYASHI T, ABE K, KOGURE K: Effects of a new calcium channel blacker, KB-2796, on protein synthesis of the CA1 pyramidal cell and delayed neuro-nal death following transient forebrain ischaemia. J. Neurochem. (1989) 53:1589–1594.
   PubMed Web of Science ®Google Scholar
• ARAKI T, KOGURE K, NISH1OKA K: Comparative neuro-protective effects of pentobarbital, vinpocetine, flu-narizine and ifenprodil on ischaemic neuronal damage in the gerbil hippocampus. Res. Exp. Med. (1990) 190:19–23.
   PubMed Web of Science ®Google Scholar
• KATO H, ARAKI T, KOGURE K: Role of the excitotoxic mechanism in the development of neuronal damage following repeated brief cerebral ischaemia in the ger-bil. Brain Res. (1990) 516:175–179.
   PubMed Web of Science ®Google Scholar
• DE RYCK M, DUYTSCHAEVER H, PAUVVELS PJ, JANSSEN PA: Ionic channels, cholinergic mechanisms, and re-covery of sensorimotor function after neocortical in-farcts in rats. Stroke (1990) 21:111158–163.
   Web of Science ®Google Scholar
• CLARK WM, MADDEN KP, ZIVIN JA: The lack of effect of flunarizine on preserving neurologic ft:action after experimental stroke. Soc. Neurosci. Absfr: (1990) 16: 935.
   Google Scholar
• GUNN AJ, GLUCKMAN PD: Flunarizine, a calcium chan-nel antagonist, is not neuroprotective when given after hypoxia-ischaemia in the infant rat. Dev. Pharmacol Ther. (1991) 17:205–209.
   PubMedGoogle Scholar
• XIE Y, SEO K, ISHIMARU K, HOSSMANN KA: Effect of calcium antagonists on post-ischemic protein biosyn-thesis in gerbil brain. Stroke (1992) 23:87–92.
   PubMed Web of Science ®Google Scholar
• DE HAAN EIFI, VAN REEMPTS JL, BORGERS M et al.: Possible neuroprotective properties of flunarizine in-fused after asphyxia in fetal lambs are not explained by effects on cerebral blood flow or systemic blood pres-sure. Pediafr: Res. (1993) 34:379–384.
   PubMed Web of Science ®Google Scholar
• GUNN AJ, WILLIAMS CE, MALLARD EC, TAN WK, GLUCK-MAN PD: Flunarizine, a calcium channel antagonist, is partially prophylactically neuroprotective in hypoxic-ischaemic encephalopathy in the fetal sheep. Pediafr. Res. (1994) 35:657–663.
   PubMed Web of Science ®Google Scholar
• RAMI A, KRIEGLSTEIN J: Neuronal protective effects of calcium antagonists in cerebral ischaemia. Life Sci. (1994) 55:2105–2113.
   PubMed Web of Science ®Google Scholar
• ABE K, KOGURE K, WATANABE T: prevention of ischae-mic and post-ischemic brain oedema by a novel calcium antagonist (PN200-110) Cereb. Blood HowMetab. (1988) 8:436–439.
   Web of Science ®Google Scholar
• SAUTER A, RUDIN M: Calcium antagonist for reduction of brain damage in stroke. J. Cardiovasc. Pharmacol. (1990) 15 (Suppl.):S43–S47.
   Google Scholar
• SAUTER A, RUDIN M: Prevention of stroke and brain damage with calcium antagonists in animals. Am. J. Hypertens. (1991) 4:121S–127S.
   Google Scholar
• NAKANE H, 00BOSHIH, IBAYASHI S et al: Isradipine, acalcium channel blacker, attenuates the ischaemia-in- duced release of dopamine but not glutamate in rats. NeuroscL Lett. (1995) 188:151–154.
   PubMed Web of Science ®Google Scholar
• BAILEY SJ, WOOD NI, SAMSON NA et al.: Failure of isradipine to reduce infarct size in mouse, gerbil and rat models of cerebral ischaemia. Stroke (1995) 26:2177–2183.
   PubMed Web of Science ®Google Scholar
• MARINOV M, WASSMANN H: Lack of effect of PN 200-110 on neuronal injury and neurological outcome in middle cerebral artery-occluded rats. Stroke (1991) 22:1064–1067.
   PubMed Web of Science ®Google Scholar
• KAMEI K, TSUCHIDA S, TAGUCHI K, NISH1KIBE M: Effect of a new calcium entry blacker, NB-818, on delayed neuronal death in the ischaemic gerbil hippocampus. Jpn.j Pharmacol (1991) 56:279–286.
   PubMedGoogle Scholar
• SADOSH1MA S, IBAYASHI S, NAKANE H eta].: Attenuation of ischaemic and post-ischemic damage to brain meta-bolism and circulation by a novel Ca2+ channel antago-nist, NC-1100, in spontaneously hypertensive rats. Eur. Pharmacol. (1992) 224:109–115.
   Google Scholar
• NISHIJO H, KUZE S, ONO T eta].: Calcium entry blacker ameliorates ischaemic neuronal damage in monkey hippocampus. Brain Res. Bull. (1992) 29:519–524.
   Google Scholar
• NISHIJO H, TABUCHI E, ONO T etaL: Physiological results of monkey brain ischaemia, and protection by a cal-cium blacker. Brain Res. Bull. (1995) 37:89–101.
   PubMed Web of Science ®Google Scholar
• CHEW W, KUCHARCZYK J, MOSELEY M, DERUGIN N, NORMA D: Hyperglycemia augments ischaemic brain injury: in vivo MR imaging/spectroscopic study with nicardipine in cats with occluded middle cerebral ar-teries. Am. J. Neuroradiol (1991) 12:603–609.
   PubMed Web of Science ®Google Scholar
• KAWAMURA S, SHIRASAWA M, FUKASAWA H, YASUI N: Effects of Ca2+ entry blacker (nilvadipine) on acute focal cerebral ischaemia in rats. Exp. Brain Res. (1991) 83:434–438.
   PubMed Web of Science ®Google Scholar
• KAWAMURA S, U Y, SHIRASAWA M, YASUI N, FUKASAWA H: Protective effect of nilvadipine on focal cerebral ischaemia in spontaneously hypertensive rats. Neurol Med. Chk. (Tokyo) (1996) 36:151–155.
   PubMedGoogle Scholar
• SHIINO A, MATSUDA M, SUSUMU T, HANDA J: Effects of the calcium antagonist nilvadipine on focal cerebral ischaemia in spontaneously hypertensive rats. Surg. Neurol (1991) 35:105–110.
   PubMed Web of Science ®Google Scholar
• TAKAKURA S, SUSUMU T, SATOH H et al.: Nilvadipine - a new calcium channel blacker reduces ischaemic brain damage in rats. Jpn. Pharmacol. (1991) 56:547–50.
   PubMedGoogle Scholar
• KAWAMURA S, SHIRASAWA M, FUKASAWA H, YASUI N: Attenuated neuropathology by nilvadipine afte r middle cerebral artery occlusion in rats. Stroke (1991) 22:51–55.
   PubMed Web of Science ®Google Scholar
• TAKAKURA S, FURUICHI Y, SATOH H, MORI J, KOHSAKA M: Effects of nilvadipine on neuronal function in the ischaemic cat brain. Surg. Neurol. (1992) 37:255–260.
   PubMed Web of Science ®Google Scholar
• LI Y, KAWAMURA S, YASUI N, SHIRASAWA M, FUKASAWA H: Therapeutic effects of nilvadipine on rat focal cere-bral is chaemia. Exp. Brain Res. (1994) 99:1–6.
   PubMed Web of Science ®Google Scholar
• BARONE FC, PRICE WJ, JAKOBSEN P, SHEARDOWN MJ, FEUERSTEIN G: Pharmacological profile of a novel neuronal calcium channel blacker includes reduced cerebral damage and neurological deficits in rat focal ischaemia. Pharmacol Biochem. Behav. (1994) 48:77–85.
   PubMed Web of Science ®Google Scholar
• MOLLER A, CHRISTOPHERSEN P, DREJER J et al. Pharma- cological profile and anti-ischaemic properties of the Ca(2-0-channel blacker NS-638. Neurol Res. (1995) 17:353–360.
   PubMed Web of Science ®Google Scholar
• BENHAM CD, BROWN TH, COOPER DG eta].: SB 201823-A a neuronal Ca2+ antagonist is neuroprotective in two models of cerebral ischaemia. Neuropharmacology (1993) 32.1249–57.
   Google Scholar
• BARONE FC, LYSKO PG, PRICE WJ et al: SB 201823-A antagonizes calcium currents in central neurones and reduces the effects of focal ischaemia in rats and mice. Stroke (1995) 26:1683–9.
   PubMed Web of Science ®Google Scholar
• VALENTINO K, NEWCOMB R, GADBOIS T eta].: A selective N Type calcium channel antagonist protects against neuronal loss afte r global cerebral ischaemia. Proc. Natl. Acad. Sci. (1993) 90:7894–7971.
   Google Scholar
• BUCHAN AM, GERTLER SZ, LI H eta].: A selective N Type Ca2±-channel blacker prevents CA1 injury 24 h follow-ing severe forebrain ischaemia and reduces infarction following focal ischaemia. j Cereb. Blood How Metab. (1994) 14:903–910.
   Google Scholar
• TAKIZAWA S, MATSUSHIMA K, FUJITA H eta].: A selective N Type calcium channel antagonist reduces extracellu-lar glutamate release and infarct volume in focal cere-bral ischaemia. J. Cereb. Blood Mow Metab. (1995) 15:611–618.
   Google Scholar
• LIMBURG M, HIJDA A: Flunarizine in acute ischaemic stroke: a pilot study. Eur. Neurol. (1990) 30:121–122.
   PubMed Web of Science ®Google Scholar
• FRANKE CL, PALM R, DALBY M et a].: Flunarizine in stroke treatment (FIST): a double-blind, placebo-con-trolled trial in Scandinavia and the Netherlands. Acta Neurol. Scand. (1996) 93:56–60.
   Google Scholar
• GINSBERG MD, LIN B, MORIKAWA E et al: Calcium antagonists in the treatment of experimental cerebral ischaemia. ArzneimforschAkug Res. (1991) 41:334–337.
   PubMed Web of Science ®Google Scholar
• PICKARD JD, MURRAY GD, ILLINGSWORTH R: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British Aneurism Ni-modipine Trial. Br. Med. J. (1989) 298:636–642.
   PubMed Web of Science ®Google Scholar
• KAKARIEKA A, SCHAKEL H, FRITZE J: Clinical experi-ences with nimodipine in cerebral ischaemia. Neurol Trans. (1994) 43 (Suppl.):13–21.
   Google Scholar
• GELMERS HJ, HENNERICI M: Effect of nimodipine on acute ischaemic stroke, pooled results from five ran-domised trials. Stroke (1990) 21 (Suppl.):IV81–84.
   Google Scholar
• TRUST STUDY GROUP: Randomised, double-blind, pla-cebo-controlled trial of nimodipine in acute stroke. Lancet (1990) 336:1205–1209.
   PubMed Web of Science ®Google Scholar
• MURPHY JJ: Randomised, double-blind, placebo control-led trial of nimodipine in acute stroke. Lancet (1990) 336:1205–1209.
   PubMed Web of Science ®Google Scholar
• BOGOUSSLAVSKY J: Double-blind study of nimodipine in non-severe stroke. Eur. Neurol. (1990) 30:23–30.
   PubMed Web of Science ®Google Scholar
• MARTINEX VILA E, GUILLEN F, VILLANUEVA JA et al.: Placebo-controlled trial of nimodipine with treatment of ischaemic cerebral infarction. Stroke (1990) 21:1023–1028.
   PubMed Web of Science ®Google Scholar
• WILMALARATNA S, CAPILDEO R: Nimodipine in acute ischaemic stroke. J. Neurol. (1990) 237:146.
   Google Scholar
• KRAMER G, TETTENBORN B, AICHNER F: Nimodipine in acute ischaemia stroke, results of the nimodipine Ger- man-Austrian stroke trial. Neurology (1990) 40(Suppl.):415–416.
   Google Scholar
• AMERICAN NIMODIPINE STUDY GROUP: Clinical trial of nimodipine in acute ischaemic stroke. Stroke (1992) 23:3–8.
   PubMed Web of Science ®Google Scholar
• YAO L, DING D: Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral in-farction. J. Neurol Neurosurg. PsychiaL (1990) 55:844–846.
   Web of Science ®Google Scholar
• GELMERS HJ, GURTER K, DEWEERDT CJ, WIEZER HI-U: A controlled trial of nimodipine in acute ischaemic stroke. New Engl. J. Med. (1988) 318:203–207.
   PubMed Web of Science ®Google Scholar
• PACI A, OTTAVIANO P, TRENTA A et al: Nimodipine in acute ischaemia stroke. Acta. Neurol Scand. (1989) 80:282–286.
   PubMed Web of Science ®Google Scholar
• ZORROW MH AND PROUGH DS: Properties of calcium channel blockers. New Horizons (1996) 4:107–114.
   PubMedGoogle Scholar
• FISHER M, GROTTA J: New uses for calcium channel blockers. Therapeutic implications. Drugs (1993) 46:961–75.
   Google Scholar
• ALBORCH E, SALOM JB, TORREGROSA G: Calcium chan-nels in cerebral arteries. Pharmacol 7her. (1995) 68:1–34.
   Google Scholar